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1. Introduction
Conventional treatment options for organ confined prostate cancer range from active surveil‐
lance to whole gland radical therapy. Active surveillance has the distinct advantage of
avoiding over treatment and treatment related morbidity but carries the risk of silent progres‐
sion of prostate cancer in up to 35 % of cases [1]. It may also induce no treatment related
significant anxiety and uncertainty [2]. Radical therapy has the advantage of improving the
overall and cancer specific survival in appropriately selected patients [3-4] but bears significant
risk of treatment related functional complications that detrimentally affect quality of life [5-6].
Therefore, counseling patients for appropriate, individual treatment strategy remains chal‐
lenging even for experienced physicians.
Consequently, focal therapy has emerged as an alternative option to standard therapies. The
goal of this tissue preserving strategy as defined by the International Task Force on Prostate
Cancer and the Focal Lesion Paradigm would be to ‘selectively ablate(s) known disease and
preserve(s) existing functions, with the overall objective of minimizing lifetime morbidity
without compromising life expectancy [7]. A number of focal therapy energies and modalities
have commonly been used [8]. Among these therapies, High Intensity Focused Ultrasound
(HIFU) emerged as a valid mini invasive therapy for localised prostate cancer, using focused
ultrasound to generate areas of intense heat to induce tissue necrosis. This energy delivery
system originally used to treat the whole prostate is used nowadays to treat a part of the gland.
Many case series have reported encouraging short term functional and oncological results of
men with prostate cancer treated primarily in a focal manner [8-19]. Recently, we have
published the first mid-term report (median follow up of 38 months) of focal HIFU for a
clinically unilateral prostate cancer.
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2. Basic physics of waves and ultrasound
To understand the basic principle of high intensity focused ultrasound as an ablative treatment
modality for prostate cancer, the main properties of sound waves should be known and are
summarized in figure 1 and 2.
Figure 1. Physical parameters of sound physics
Sound is defined as a mechanical disturbance from a state of equilibrium that propagates
through an elastic material medium in the form of vibrating waves. These vibrating waves
transport energy from its source to another area as long as a medium is present. The energy
transported by sound is known as acoustic energy or sonic energy. Sonic intensity (SI), defined
as a time-average rate of sonic energy-flow through a unit area (SI unit: W/cm2), is proportional
to sonic pressure square and has a positive correlation with the power and energy of sound.
This implies that the amount of energy accumulating at a target area is larger when the sonic
pressure or intensity increases. The latter parameter varies with space and time, and it is
usually expressed as peak or average intensity, and both quantities can refer to either a spatial
or temporal dimension (e.g. ISP = spatial peak intensity, ISATA = spatial average, temporal
average intensity). The frequency of a wave is derived from the amount of cycles per unit of
time. Ultrasound (US) is a form of sound that has a frequency higher than the frequency
detected by human ear (> 20.000 Hz vs. 20-20.000 Hz). HIFU therapy utilizes high intensity US
waves that are propagated through human tissues. In contrast to other ablative therapies, HIFU
therapy operates without the need of an electrode or antenna to deliver its waves. However,
the main challenge of such a technique is focusing energy-accumulation at the target area to
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induce significant biological reactions without causing harm to the intervening and surround‐
ing tissues. Recently, a phased array US transducer technique was adopted for focal HIFU
treatment. It sends temporally different sets of electronic signals to each specific transducer
component, thus enabling beam-steering and focusing, which can move a focal spot in virtually
any direction within physically allowed ranges. This system is not only more versatile than
other systems but also highly efficient without any sonic attenuation [20].
3. Biological interactions of US
Since the mid 1950, US have been extensively used for diagnostic procedures without any
detrimental effect on the human body [21]. However, it must be noted that US waves used for
therapeutic purposes could be potentially dangerous. In fact, it carries energy that causes
biological reactions in various ways. The most important are the thermal (hyperthermia) and
non thermal (acoustic cavitation) effects [22-23]. The thermal effect is tissue heating and protein
denaturation can occur at a temperature of 56°C [24-25]. Protein denaturation contributes to a
subsequent coagulation necrosis (thermal ablation). The effect is a function of the wave
amplitude and pulse frequency. Acoustic cavitation is defined by the creation and develop‐
ment of bubbles or cavities. The violent oscillation and collapse in US fields of these bubbles
cause a significant degree of mechanical and thermal effects. Mechanical and cavitation tissue
effects are caused by high amplitudes and ultra-short pulse wave, with amplitude reaching
100 Mpa and a pulse of 1-2 ms. Moderate pressure amplitude of 10 Mpa and continuous wave
of 1 s are the cause of thermal effects. Short ultrasound pulses and low amplitude up to 1 Mpa
Figure 2. HIFU uses high energy US waves generated from numerous sources and focuses them to a small spot.
Acoustic pressure is rapidly elevated near focus where tissue temperatures are also raised to level that is sufficient for
coagulation necrosis
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causes no significant heating, but cavitation caused by this type of waves are used in some
circumstances like enhancing a drug delivery or the transient opening of the blood-brain
barrier [22].
4. Mechanisms of action of high intensity focused ultrasound
The technique is based on the generation of focused ultrasound field. The focused ultrasound
field is generated by a piezoelectric transducer with a center frequency of 1 to 7 MHz. The field
is coupled into the body and aimed into a target region. Ultrasound waves are absorbed by
tissues throughout their propagation and the acoustic energy will be converted to heat with a
high energy density inside the focal zone [22]. The result is a temperature rise in the target
zone within seconds to a level exceeding the threshold level of protein denaturation which is
around 60 degrees. The result will be protein coagulation and coagulative necrosis [22-24]. In
contrast there is a low acoustic energy density in the surrounding structures which keep them
spared. This will create elliptical small volume lesions of 50-300 mm3. Larger volume can be
ablated without gaps by combining single lesions.
Between sonication a pause is necessary to prevent boiling and bubbles formations which can
reflects and distort the ultrasound field and the consequence is unpredictable lesion growth
and lesion formation in unwanted areas. So to ablate a large solid tumor it can take several
hours. Thus HIFU is a very time consuming procedure [22]. HIFU has the advantage over other
thermal ablative techniques of being a mini-invasive and non-ionizing with no long-term
cumulative effects which means that it could be safely repeated. Further more it is interesting
non invasive surgical tool because it can cause cell death in a tissue that is distant from the
source of US [23].
5. Clinical devices in use
There are two main types of transducers used for HIFU. In general HIFU needs a high power
ultrasound transducer. Such kind of transducers is made of low loss piezoceramic materials
or piezocomposites working in resonant mode. The two major types are the self- focusing
spherical shaped piezoceramic transducers with fixed aperture and fixed focal length which
is the simplest, and the phased array transducers made up of a large number of separate
transducer elements. Thereby each element is driven by a separate electric radio frequency
signal with an individual phase, frequency and amplitude. The advantages of phased arrays
are the possibility for an adaptive selection of elements, the fast electronic beam steering and
the beam forming capability. Such transducers are much more expensive and the number of
elements in such transducers can reach thousands in some special cases [22].
On the other hands we can divide the transducers into extracorporeal used for the treatment
of cutaneous and abdominal tumors, transrectal as those used for the prostate, and interstitial
and endoscopic ones used for the treatment of biliary or esophageal lesions [24].
Cancer Treatment4
6. Guiding/monitoring of therapy
Therapy guidance is the key for a safe and effective HIFU. Guidance is accomplished mainly
with two imaging methods which are US and MRI. Imaging techniques are used with HIFU
therapy not only for therapeutic guidance but it allows also therapy planning and targeting,
monitoring, controlling and assessing the treatment response and follow-up [22].
6.1. Ultrasound monitoring
This is the case of most today’s HIFU treatment. In general the divergent field of the diagnostic
transducer and the field of therapeutic source are superposed and arranged in parallel so that
the diagnostic imager provides the beam view. This eases the positioning of the therapeutic
source and the identification of organ at risk [22]. Real-time visualization of the targeted
volume is feasible with decoupling of US image and focused US.
US are able to detect cloud of gas bubbles that are formed as results of cavitation and tissue
heating. The detection of bubble could be an indication for the position of the thermal focus,
but this cannot be used to assess and control lesion formation.
US are not able to perform temperature mapping. Some try to use some parameters such as
speed of sound, or attenuation or reflection coefficient as indicators for temperature variations,
but with modest success.
The major advantages of US are, first they share same physical mechanism so a good assess‐
ment of the beam pass is possible. Then it allows the use of conventional materials for the
therapy unit so that the diagnostic US transducer can be easily integrated in the therapeutic
source that allows for a small and flexible devices with lower prices [22].
6.2. MR-monitoring
The advantages of MRI over US are the capacity of giving a morphological image for planning,
targeting and thermal monitoring. It can also assess the shape and size of the induced tissue
lesion at the end of therapy. Contrast enhanced T1 imaging are employed. The induced lesions
prove hypointense reflecting the loss of perfusion. Major disadvantage is the need for an MR
compatible HIFU therapy unit and the cost of the MR scanner. Limitations are the confined
space for patient access and the need of a complex and expensive technology [22].
6.3. MR thermometry
A different method exists to measure the temperature related changes with the MR. Mainly
four methods have been described: T1, diffusion, proton density, and proton resonance
frequency shift. The most frequently used method is the proton resonance frequency shift
(PRFS). The proton resonance frequency shift can be measured directly or by phase mapping
which consists of observing the phase shift induced by temperature change. Phase mapping
is easier to do than direct assessment. Therefore phase mapping is the most common approach
used for temperature mapping [22].
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7. HIFU Therapy for prostate cancer: Its role in focal therapy
HIFU for the treatment of localized prostate cancer was developed in 1990. Nowadays there
are two available devices for the treatment of prostate cancer: the Ablatherm™ (EDAP TMS
S.A., Vaulx-en-Velin, France) and the Sonablate™ (Focus Surgery, Inc, Indianapolis, Indiana,
USA) [26].
Both of them have a simultaneous imaging technique coupled to the treatment device. They
differ by patient positioning and the degree of manual control of power. Currently, the
technique is used among many cancer centers despite the fact that available guidelines do not
recommend it for the treatment of localized prostate cancer. In 2010, the Cancer Care Ontario
group excluded HIFU from its recommendations due to lack of randomized controlled clinical
trials and short follow up [27]. The NICE guidelines in 2012 considered HIFU as an experi‐
mental technique with further studies needed in order to conclude [28]. In 2014, the FDA bans
the use of HIFU for whole-gland primary treatment of clinically localized prostate cancer. At
present, high quality evidence on efficacy and safety of HIFU is based on uncontrolled case
series with a significant overlap of patients among series. There are no direct comparisons with
active surveillance or whole gland radical therapies. Furthermore, the technique is not
standardized and patient selection is not unanimous. The ideal candidate is defined as a patient
aged > 70 years of age, with clinical stage T1-T2 N0M0, a Gleason score<7, a PSA level <15 ng/
ml and a prostate volume of <40 ml, in particular if the patient is unsuitable for or refuse radical
therapy [26]. A prostate volume of >40 ml and the presence of large calcifications are a
contraindications for HIFU. In such cases where the volume exceed 40 ml a TURP or a
cytoreductive androgen deprivation therapy or a 5 alpha reductase inhibitor before HIFU is
recommended to reduce the volume of the prostate. The number of HIFU treatment per patient
varies between one and five. The median follow up time is short with the longest series
reporting data after a median follow up of 94 months [29].
HIFU could be used as a primary treatment or as a salvage therapy in recurrent prostate cancer
after radiotherapy failure. The field could involve a whole gland ablation or a more focal therapy.
For technical considerations, Hemiablation HIFU of an entire lobe delivered with intention to
treat is currently used for focal therapy. The technique was demonstrated to be feasible and
functional and disease control outcomes were encouraging at 3 years of follow up.
8. The principle rationale of tissue preservation is harm reduction and
functional preservation
Adverse events affecting the urinary tract are reported in 2-58% of whole gland HIFU therapy
in the literature. Rectal toxicities ranged from 0 to 15%. Erectile dysfunction is reported in 0 to
39% of cases [30]. Toxicity rates are believed to be lower after focal therapy. In our case series,
31 consecutive patients with unilateral organ confined prostate cancer were primarily treated
by hemiablation HIFU. Early self-resolving LUTS were the most common complications and
no rectal toxicities were reported. The strategy was well tolerated in the genitourinary
functional domains: all patients were pad free continent despite a high number of apical lesions
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(n=12) and only 25% of men in our cohort of relatively elderly patients (average age 71 years)
who were potent preoperatively reported having ED post hemiablation. The procedure could
possibly be delivered in an ambulatory care setting [19].
9. Monitoring of patients after focal HIFU
In the literature, there is no consensus on whether cancer control in focal therapy should be
considered the absence of any cancer or the absence of clinically significant cancer and whether
this should be limited to the treated or untreated area. In addition there is no standard follow
up protocol for the assessment of clinical failure. In our opinion, histologic confirmation of
complete ablation within the treated area appears to be essential in focal therapy. That’s why
any positive biopsy in the treated lobe independently of the percentage of core involvement
should be considered a clinical failure. In contrast, controlateral positive biopsy should not be
considered as a clinical failure but as a technical limitation. As a surrogate, although PSA
testing is accepted as a valid outcome in standard therapy, there are no validated biochemical
measures in tissue preservation. Furthermore, PSA values are difficult to interpret in the follow
up because many factors influence post treatment values (the proportion of initial PSA that
was due to tumor, amount of residual prostate tissue, progression of BPH, TURP...). Definitions
that are currently used and validated for biochemical failure in whole gland radiation therapy
(ASTRO, Phoenix, Stuttgart...) are used, without any evidence or validation, in whole gland
HIFU and focal therapy [31]. Phoenix criteria should not be considered as response criteria to
define failure but as a threshold to offer biopsy. We believe that a specific PSA based definition
is unlikely to be derived and multiparametric MRI will play a major role in the future in the
definition of failure if it is validated against histology outcomes.
10. Oncologic outcomes
Following whole gland ablation therapy, negative biopsy rates at 3 month of 51-96% and
64-87% with Ablatherm and Sonablate respectively were reported [32-36]. Overall survival
rates and prostate cancer specific survival rates were 90% and 100% at 5 years and 83% and
98% at 8 years, respectively. The actuarial biochemical failure–free survival rates at 5 and 7
years were 77% and 69%, respectively. The actuarial disease–free survival rate at 5 and 7 years
were 66% and 59%, respectively [32-36]. Biochemical success or failure rate was stratified
against risk category according to the D’Amico classification in the majority of reports and was
uniformly more favourable for the low and intermediate risk category compared to the high
risk category. Some authors have argued that HIFU is a coagulative technology that unlike
radiation therapy results in complete cell destruction independently of Gleason score.
However, high grade tumours in prostate cancer are associated with increased neoangiogen‐
esis responsible of a heat sink phenomenon that is tissue cooling by blood flow that causes
thermal loss. The tissue under ablation in high grade tumour may be inadequately ablated and
is a high risk site for persistent residual progressive disease and metastatic spread. Following
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focal therapy, we demonstrated a biochemical recurrence free survival of 100%, 89%, 82.7% at
1, 2 and 3 years respectively, with an overall and cancer specific survival of 100% [19].
11. Limitations and Future perspectives
As any other interventional technique, there are some limitations for HIFU that must be
mentioned. First, there are factors to take into account such as collateral damage to the tissues
and the fact that the technique is operator dependent [37]. Second, the lack of comparative
trials precludes any conclusion regarding the added value of HIFU treatment compared to
active surveillance or radical therapies. Urological societies recommend using focal HIFU in
controlled trials in order to provide the needed answers. In the future, the use of focal HIFU
will not be limited to prostate cancer but will widespread to other applications. The two most
interested research topics are focused ultrasound mediated targeted drug delivery and the
transient and reversal opening of the blood-brain barrier
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